Janney Montgomery Scott’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-17,844
Closed -$435K 2757
2024
Q3
$435K Buy
17,844
+569
+3% +$15.2K ﹤0.01% 2068
2024
Q2
$434K Sell
17,275
-94
-0.5% -$2.67K ﹤0.01% 1992
2024
Q1
$520K Buy
17,369
+5,238
+43% +$154K ﹤0.01% 1972
2023
Q4
$386K Sell
12,131
-537
-4% -$16.9K ﹤0.01% 2077
2023
Q3
$447K Sell
12,668
-19,491
-61% -$743K ﹤0.01% 1844
2023
Q2
$1.22M Buy
32,159
+2,247
+8% +$89.6K ﹤0.01% 1308
2023
Q1
$1.13M Buy
29,912
+19,702
+193% +$757K ﹤0.01% 1252
2022
Q4
$433K Sell
10,210
-206
-2% -$8.49K ﹤0.01% 1868
2022
Q3
$335K Buy
10,416
+775
+8% +$27.2K ﹤0.01% 1931
2022
Q2
$313K Buy
9,641
+132
+1% +$4.28K ﹤0.01% 1891
2022
Q1
$344K Buy
9,509
+58
+0.6% +$1.99K ﹤0.01% 1823
2021
Q4
$374K Buy
9,451
+870
+10% +$36.3K ﹤0.01% 1875
2021
Q3
$375K Buy
8,581
+96
+1% +$4.31K ﹤0.01% 1835
2021
Q2
$346K Buy
8,485
+893
+12% +$34.5K ﹤0.01% 1837
2021
Q1
$249K Sell
7,592
-442
-6% -$16.6K ﹤0.01% 1951
2020
Q4
$327K Buy
8,034
+604
+8% +$22.6K ﹤0.01% 1839
2020
Q3
$272K Buy
+7,430
New +$269K ﹤0.01% 1761

Other funds holding GMAB

Janney Montgomery Scott's GMAB Position: Q4 2024 in Review

Janney Montgomery Scott sold out of Genmab (GMAB) in Q4 2024, closing a stake of 17,844 shares — an estimated $435K sold.

Janney Montgomery Scott first reported a position in GMAB in Q3 2020 and held it in 17 quarters. The position peaked at $1.22M in Q2 2023. 228 funds tracked by Wall St. Rank hold GMAB as of Q4 2024.

  • Janney Montgomery Scott reported no remaining Genmab position as of Q4 2024 after selling out during the quarter.
  • Janney Montgomery Scott sold 17,844 Genmab shares in Q4 2024, an estimated $435K.
  • Janney Montgomery Scott first reported a position in Genmab in Q3 2020 and held it in 17 quarters.
  • Janney Montgomery Scott's Genmab position peaked at $1.22M in Q2 2023.
  • 228 funds tracked by Wall St. Rank held Genmab as of Q4 2024.

Based on Janney Montgomery Scott's 13F filing for Q4 2024, filed 17 Jan 2025.